98 filings
8-K
OLMA
Olema Pharmaceuticals Inc
15 May 24
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
7:06am
10-Q
2024 Q1
OLMA
Olema Pharmaceuticals Inc
Quarterly report
8 May 24
4:15pm
8-K
OLMA
Olema Pharmaceuticals Inc
8 May 24
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:06pm
ARS
2023 FY
OLMA
Olema Pharmaceuticals Inc
26 Apr 24
Annual report to shareholders
5:15pm
DEFA14A
OLMA
Olema Pharmaceuticals Inc
26 Apr 24
Additional proxy soliciting materials
5:10pm
S-8
ballc0wa
11 Mar 24
Registration of securities for employees
4:31pm
8-K
9n602
11 Mar 24
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
4:05pm
424B3
lvyl0j ndaz
12 Feb 24
Prospectus supplement
5:16pm
EFFECT
wc0tyuz8jt9gyb6r2dl
12 Feb 24
Notice of effectiveness
12:15am
UPLOAD
5pd6aixf
7 Feb 24
Letter from SEC
12:00am
CORRESP
z9vpd7q7isw
7 Feb 24
Correspondence with SEC
12:00am
8-K
joqoq89e
8 Jan 24
Olema Oncology JP Morgan Conference January 2024
9:07am
8-K
y8p3huvy
8 Jan 24
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
8:18am
8-K
zoufy
5 Jan 24
Entry into a Material Definitive Agreement
5:26pm
424B5
w2m3844hexs zejafh
5 Jan 24
Prospectus supplement for primary offering
5:25pm
8-K
1oewplv3 d7zd3
6 Dec 23
Regulation FD Disclosure
7:48am
8-K
m1rcg14fa03x6 n9
5 Dec 23
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
5:15pm